SCHEMBL5415404

SCHEMBL5415404

Cc1nc2c3c(c(C(=O)NC4CC4)cn2c1C)CC[C@H](c1ccccc1)O3

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATP4A P20648 1/20 0.42
ATP4B P51164 1/20 0.42
BRD4 O60885 4/20 0.39
CYP3A4 P08684 2/20 0.38
CYP2C9 P11712 2/20 0.38
CCNA2 P20248 1/20 0.37
CDK2 P24941 1/20 0.37
CCNA1 P78396 1/20 0.37
HPGD P15428 1/20 0.37
TSHR P16473 1/20 0.37
SLC8A1 P32418 1/20 0.36
RAB9A P51151 1/20 0.36
LMNA P02545 1/20 0.36
MAPK1 P28482 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
CNR2 P34972 1/20 0.35
KDM4E B2RXH2 1/20 0.35
POLB P06746 1/20 0.35
MAPT P10636 1/20 0.35
TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5421021 1.00 ATP4A (0.42) ATP4AATP4BBRD4CYP3A4CYP2C9
SCHEMBL5417158 1.00 ATP4A (0.42) ATP4AATP4BBRD4CYP3A4CYP2C9
SCHEMBL5414013 0.96 ATP4A (0.41) ATP4AATP4BBRD4CYP3A4CYP2C9
SCHEMBL5567363 0.91 ATP4A (0.44) ATP4AATP4BBRD4CYP3A4CYP2C9
SCHEMBL5570682 0.91 ATP4A (0.44) ATP4AATP4BBRD4CYP3A4CYP2C9
SCHEMBL5566450 0.91 ATP4A (0.44) ATP4AATP4BBRD4CYP3A4CYP2C9
SCHEMBL5411682 0.89 ATP4A (0.44) ATP4AATP4BCYP3A4CYP2C9CCNA2
SCHEMBL5989112 0.88 ATP4A (0.46) ATP4AATP4BCYP3A4CYP2C9HPGD
SCHEMBL5417817 0.88 ATP4A (0.46) ATP4AATP4BCYP3A4CYP2C9HPGD
SCHEMBL5422357 0.87 ATP4A (0.41) ATP4AATP4BCYP3A4CYP2C9SLC8A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070191334-A1 Tricyclic imidazopyridines ALTANA PHARMA AG (DE) 2007-08-16 US disclosed
EP-1735318-A2 7H-8,9-DIHYDRO-PYRANO(2,3-C)IMIDAZO(1,2A)PYRIDINE DERIVATIVES AND THEIR USE AS GASTRIC ACID SECRETION INHIBITORS Altana Pharma AG (DE) 2006-12-27 EP disclosed
WO-2005090358-A2 7H-8,9-DIHYDRO-PYRANO (2,3-C) IMIDAZO (1,2A) PYRIDINE DERIVATIVES AND THEIR USE AS GASTRIC ACID SECRETION INHIBITORS ALTANA PHARMA AG (DE) 2005-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191334-A1 Tricyclic imidazopyridines GIPR, SLC10A2, MLNR ATP4A 131/4885ATP4B 510/4885BRD4 2342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.